masitinib ALS
Selected indexed studies
- Advances in Understanding and Treating Amyotrophic Lateral Sclerosis (ALS): A Comprehensive Review. (Cureus, 2023) [PMID:38090405]
- Masitinib: The promising actor in the next season of the Amyotrophic Lateral Sclerosis treatment series. (Biomed Pharmacother, 2023) [PMID:36774721]
- Safety of masitinib in patients with neurodegenerative diseases: a meta-analysis of randomized controlled trials. (Neurol Sci, 2024) [PMID:38627298]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Advances in Understanding and Treating Amyotrophic Lateral Sclerosis (ALS): A Comprehensive Review. (2023) pubmed
- Masitinib: The promising actor in the next season of the Amyotrophic Lateral Sclerosis treatment series. (2023) pubmed
- Safety of masitinib in patients with neurodegenerative diseases: a meta-analysis of randomized controlled trials. (2024) pubmed
- Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial. (2025) pubmed
- Masitinib as a neuroprotective agent: a scoping review of preclinical and clinical evidence. (2024) pubmed
- The Scientific and Therapeutic Rationale for Off-Label Treatments in Amyotrophic Lateral Sclerosis. (2024) pubmed
- Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. (2020) pubmed
- In pursuit of the normal progressor: the holy grail for ALS clinical trial design? (2020) pubmed
- ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment? (2017) pubmed
- Motor Neuron Disease Systematic Multi-Arm Adaptive Randomised Trial (MND-SMART): a multi-arm, multi-stage, adaptive, platform, phase III randomised, double-blind, placebo-controlled trial of repurposed drugs in motor neuron disease. (2022) pubmed